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Background: The purpose of this study was to develop a transdermal ligustrazine patch 
c  ontaining a stable formulation and with good entrapment efficiency, release rate, and t  ransdermal 
absorption.
Methods: Ligustrazine ethosomes were prepared by ethanol injection-sonication, with 
e  ntrapment efficiency as an indicator. Using acrylic resin as the primary constituent, the 
l  igustrazine ethosome patch was prepared by adding succinic acid as a crosslinking agent and 
triethyl citrate as a plasticizer. In vitro release and transdermal permeation studies were carried 
out. Finally, a pharmacokinetic study was carried out in rats to explore relative bioavailability. 
The formulations of ligustrazine ethosome were 1% (w/v) phospholipid, 0.4% (w/v) cholesterol, 
and 45% (v/v) ethanol.
Results: Ligustrazine ethosomes were obtained with an average particle size of 78.71 ± 1.23 nm 
and an average entrapment efficiency of 86.42% ± 1.50%. In vitro transdermal testing of the 
ligustrazine ethosome patches showed that the cumulative 24-hour amount of ligustrazine was 
up to 183 ± 18 µg/cm2. The pharmacokinetic results revealed that the relative bioavailability 
was 209.45%.
Conclusion: Compared with conventional ligustrazine administration, ligustrazine etho-
some patches could promote better drug absorption and increase bioavailability. This 
study d  emonstrates that the transdermal action of the ligustrazine ethosome patch was 
comparatively good.
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Introduction
Ligustrazine has the chemical name 4-methyl-pyrazine (tetramethylpyrazine), 
with a chemical formula of C8H12N2 and a molecular weight of 136.2. A tr  aditional 
Chinese medicine for angina pectoris, ligustrazine plays a role in expanding 
blood vessels, increasing coronary and cerebral blood flow, preventing platelet 
a  ggregation, i  nhibiting thrombosis, and improving the microcirculation.1 It has low 
toxicity, although 30 cases of adverse drug reactions have been reported, including 
a  naphylactic shock, erythra, angioneurotic edema, angina pectoris, hypotension, 
acute transient ischemic attack, severe headache, prematurity, severe gastrointestinal 
reactions, and severe asthma.2
Because angina pectoris is associated with high morbidity, is a chronic condition, and 
requires long-term medication, a transdermal patch for drug delivery would be a good 
choice for treatment. Compared with conventional oral administration, drug delivery by a 
dermal patch has the advantages of avoiding first-pass hepatic   metabolism and destruction International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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in the gastrointestinal tract, reducing side effects, improving 
compliance with medication, and dosage control.3
Flexible liposomes are common vectors in transdermal 
drug-delivery systems, with relatively good liquidity and 
deformability. Currently there are three types of flexible 
l  iposomes, ie, transfersomes, ethosomes, and niosomes. 
In recent years, ethosomes have become new liposome 
  carriers with high deformability, high entrapment efficiency, 
and a good transdermal permeation rate in the drug-delivery 
system, and are suitable for transdermal administration.4,5 
Compared with other liposomes, the physical and c  hemical 
properties of ethosomes make these more effective for 
drug delivery through the stratum corneum into the blood 
c  irculation, which is very important in the design of a trans-
dermal drug-delivery system.6,7 It has been reported that 
there were no significant changes in average particle size, 
distribution, and structure of ethosomes over two years.8 
One study has found that the size of liposomes significantly 
increased with time, while the average size of ethosomes 
basically remained constant over four weeks.9 It has also been 
found that ethosomes are well distributed when cholesterol 
is included in the formulation, and that they are prone to 
aggregation in the absence of cholesterol. It is thought that 
cholesterol stabilizes into a bilayer when ethosomes are main-
tained in a gel state, and that the high concentration of ethanol 
in ethosomes can ensure mobility of the vesicles, and that 
a moderate amount of cholesterol could ensure stability.10–12 
The purpose of this study was to develop a sustained-release 
dermal patch with a stable formulation and good entrapment 
efficiency, release rate, and transdermal absorption.
Materials and methods
Instruments and materials
The sonication instrument used in this study was purchased 
from Thermo Fisher Scientific Co (San Nicolas de los Garza, 
Mexico). The Zetasizer 1000 type laser particle size analyzer 
was obtained from Malvern Instruments (Malvern, UK). 
A MFP-3D type atomic force microscope was obtained 
from Asylum Research Co (Santa Barbara, CA). High-
performance liquid chromatography (ZorbaxSB-C18 column, 
150 mm × 4.6 mm, 5.0 µm) was from Dionex Co (Chelmsford, 
MA). The Sigma 3K30 type high-speed r  efrigerated centrifuge 
was from Sigma Co (Munich, Germany). Soybean lecithin 
was from Avanti Polar Lipids Inc (Alabaster, AL). The ligus-
trazine reference substance was obtained from the National 
Institute for the Control of Pharmaceutical and Biological 
Products (Beijing, China). The ligustrazine drug substance 
was sourced from the Huapeng Natural Plant Development Co 
Ltd (Shanxi, China), and the poloxamer was from the Tianjin 
Chemical Reagent Research Institute (Tianjin, China). Acrylic 
resin IV was obtained from the Iodine Factory (Lianyungang, 
China), and succinate was from the Dongxing Reagent Fac-
tory (Shenyang, China). T  riethyl citrate was obtained from the 
Qingpu Synthetic Reagent Factory (Qingpu, China). Azone 
was obtained from the Guangzhou Chemical Auxiliary Agent 
Factory (  Guangzhou, China). Other reagents were of analyti-
cal pure grade. Twenty-eight male Sprague Dawley rats weigh-
ing 250–300 g were obtained from the Experimental Animal 
Center of Xiangya School of Medicine (Xiangya, China).
Preparation of echosome
Ethosome was prepared by the ethanol injection-sonication 
method,13 and was composed of 1% (w/v) lecithin, 0.4% 
(w/v) cholesterol, 45% (v/v) ethanol, ligustrazine, and 
water. Lecithin was dissolved with ethanol in a glass bottle. 
Ligustrazine was dissolved in double-distilled water and 
mixed uniformly with a magnetic stirrer. A glass bottle was 
hermetically connected with a syringe, which allowed for 
addition of ethanol and avoidance of evaporation. After the 
ligustrazine was dissolved, an ethanol solution of lecithin was 
added at a flow rate of 200 µL/min, then homogenized with 
an ultrasonic probe for five minutes. Thereafter, li  gustrazine 
ethosome suspension was filtered using 0.45 µm disposable 
filters. All the procedures were performed under nitrogen 
gas at room temperature. The final concentration of the 
drug was adjusted to 10 g/L by controlling the volume. 
The empty e  thosome suspension was obtained by not adding 
any l  igustrazine during the preparation process.
Determination of particle size
The particle size of the ethosomes was measured immediately 
after preparation using a laser dynamic scattering instrument. 
The same percentage of water–ethanol solution in the etho-
some preparation (filtered with a 0.22 µm filter) was used for 
a sample diluent. Five different batches of ethosomes were 
investigated to calculate the average particle size.
Content and entrapment efficiency
Drug content was determined by high-performance liquid 
chromatography as described elsewhere.14 The entrapment 
efficiency of ligustrazine ethosomes was determined as 
previously described.15
Preparation of patch
The crosslinking agent has an impact on the performance 
of an acrylic pressure-sensitive adhesive to a certain extent. International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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In order to improve performance, succinic acid was added 
along with an acrylic resin as a crosslinking agent, and   triethyl 
citrate as a plasticizer. Appropriate amounts of acrylic resin, 
triethyl citrate, succinate, azone, and l  igustrazine ethosomes 
were well stirred to form a gel, evenly coating the back layer 
of polyethylene film. After drying at room temperature, a 
protective layer of polystyrene film was coated on the gel, thus 
obtaining the ligustrazine ethosome transdermal patch.
stability testing
Three batches of samples were sealed with aluminum foil 
pouch packaging, and kept at a constant temperature of 40°C 
and a relative humidity of 75%. The samples were collected 
at the first, second, and third month to determine their content 
and observe their stability.
In vitro release rate
Six ligustrazine ethosome patches were glued to the c  enter 
of a round square stainless steel assembly plate with a 
diameter of 90 mm and a length of 78 mm. The silver square 
hard p  lastic film was carefully peeled off. A homogenated 
d  issolution device was used, with 1000 mL of 0.9% sodium 
chloride solution as the solvent at 32 ± 0.5°C. The assembly 
plate was placed flat on the bottom of the container, keeping 
the release side upward and parallel to the homogenate edge 
as well as the surface of the dissolution medium. The bottom 
edge of the agitating vane was 25 ± 2 mm from the plate of 
the device. Air bubbles adsorbed on the release surface were 
removed. The device was then rotated at 50 rpm. A 10 mL 
sample of solution was taken, without filtering, as the test 
solution at hours 2, 4, 6, 12, and 24. At the same time, 10 mL 
of 0.9% sodium chloride solution at the same temperature 
was added to the container. The cumulative amount released 
was calculated by the drug concentration of the test solutions 
detected using high-performance liquid chromatography.
In vitro transdermal test of patch
Six healthy male Sprague Dawley rats (weight 250–300 g) 
were killed and the abdominal hair was removed. After 
washing with normal saline, the abdominal skin was peeled 
off with a scalpel, and the subcutaneous tissue and fat were 
removed. The intact rat skin was immersed into normal saline 
and stored in a refrigerator at 4°C until use within 24 hours. 
The self-modified Franz diffusion cell used in the experiment 
had a receiving chamber (central diameter 2 cm, cover area 
3.14 cm2, and volume 11.0 mL). The isolated pretreated rat 
skin was removed from the refrigerator, fixed on the modified 
Franz diffusion cell, and the horny skin orientated toward 
the release chamber. The prepared transdermal ligustrazine 
ethosome patch was then fixed to the rat skin. The receiving 
chamber was filled with normal saline 11 mL as the diffu-
sion medium because ligustrazine has better solubility in 
this medium. The surface of the isolated skin in the release 
chamber just touched the receiving solution in the receiving 
chamber. The entire diffusion chamber device was put on 
the constant-temperature magnetic stirrer and stirred con-
tinuously at 200 rpm and 37°C. The solution was removed 
from the receiving chamber at hours 1, 2, 3, 4, 5, 6, 8, 10, 12, 
16, and 24, respectively. Fresh diffusion medium was then 
added at the same volume. The solution collected was filtered 
through a 0.45 µm microporous membrane. The primary 
filtrate was discarded, and 20 µL of the subsequent filtrate 
was collected as a sample for analysis by high-performance 
liquid chromatography. The cumulative transdermal amount 
of drug was calculated according to the formula: Qn = CnV/A, 
where Cn was the correction c  oncentration of the drug at 
t time, V was the total volume of receptor s  olution, Qn was 
the c  umulative transdermal amount, and A was the effective 
diffusion area. Linear regression analysis was conducted 
according to the Qn-t curve to obtain the linear slope (dQ/
dt) and steady-state permeation rate of the drug, Js (µg⋅cm-
2⋅s-1).
Pharmacokinetic test of patch in rats
For the pharmacokinetic study, 81 male Sprague Dawley 
rats weighing 250–300 g were randomly divided into three 
groups, ie, Group A (intragastric ligustrazine, n = 27), Group B 
(t  ransdermal ligustrazine ethosome patch, n = 27), and Group C 
(conventional transdermal ligustrazine patch, n = 27). The 
dose of ligustrazine administered was 100 mg/kg. Three rats in 
each group were killed at hours 0.1, 0.2, 0.5, 1, 2, 4, 8, 12, and 
24 after administration. Thereafter, 3 mL blood (with heparin) 
was collected from the abdominal aorta, and centrifugated for 
15 minutes at 4000 rpm. The supernatant sample of blood 
plasma was taken out and adjusted to a volume of 1 mL with 
normal saline. Five percent d  iethyldithiocarbamate solution 
was added and mixed thoroughly, and then bathed in water 
for 30 minutes at 37°C. The sample was taken out and cooled 
at room   temperature, washed with 2 mL of chloroform, and 
vortexed for two   minutes. The sample was centrifugated for 
10 minutes at 2000 rpm and separated using chloroform, 
washed with chloroform again, and dried using dry air in 
a constant water bath at 37°C. The sample was dissolved in 
a 100 µL mobile phase and filtered for high-performance 
liquid chromatography detection. Finally, the plasma drug 
concentration in the three groups was   analyzed using 3p97 International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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software for p  harmacokinetic parameters. M  ethodological 
tests showed that the plasma content was in line with l  inear 
regression at 1–250 µg/mL, with a regression equation 
of A = 226.8590C + 72.2584, r = 0.9994, which met the 
r  equirements of the experiment.
statistical analysis
SPSS software (v. 13.0; SPSS Inc., Chicago, IL) was used 
for statistical analysis. Pharmacokinetic data were ana-
lyzed by 3p97 software (Chinese Pharmacological Society, 
B  eijing, China).
Results
general characteristics
Diluted ligustrazine ethosomes were measured using a laser 
particle size analyzer, and had an average particle size of 
78.71 ± 1.23 nm and a polydispersity index of 0.145 ± 0.042. 
The particle size of ligustrazine ethosomes had a narrow 
distribution, as shown in Figure 1.
The three prepared batches of ligustrazine ethosome 
samples were detected according to their compositions by 
high-performance liquid chromatography. The percentage 
content was 99.08%, 97.94%, and 98.62%, respectively, with 
an average entrapment efficiency of 86.42% ± 1.50%.
Stability testing showed that the appearance, content, 
and viscosity of the ligustrazine ethosome patches remained 
unchanged over three months, which indicated good stability 
of the patches.
In vitro release rate
The in vitro release results are shown in Table 1. The 
steady state of the release curve was fitted by zero-level and 
Higuchi equations, respectively, to generate the following 
equations:
1.  Zero-level release: M = 3.54 t + 151.02, r = 0.9897
2.  Higuchi equation: M = 19.54 t1/2 + 125.04, r = 0.9977
The correlation coefficients of these equations were com-
pared, and the Higuchi equation was found to have the optimal 
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fit. The drug release rate was 19.54 µg⋅cm-2⋅h-1/2 according 
to the linear slope of the Higuchi equation.
Transdermal performance
Cumulative transdermal and steady-state permeation rates 
are shown in Table 2.
Q-t equation: Q = 7.1753t + 20.412 (r = 0.991) · Js × 103 
(µg⋅cm-2⋅s-1) was 2.0 ± 0.9.
Pharmacokinetics
In the pharmacokinetic experiment, plasma drug concentra-
tions decreased two hours after administration in Groups A, 
B, and C. The plasma concentration of Group B was high 
and stable after two hours, as shown in Figure 2. The phar-
macokinetic results for the three groups were consistent with 
a two-compartment model. The value of the area under the 
concentration-time curve (AUC) was 80.42 µg⋅ml-1⋅h in 
Group A, 168.38 µg⋅ml-1⋅h in Group B, and 79.31 µg⋅ml-1⋅h 
in Group C. The AUC value of Group B was 2.09 times 
greater than that of Group A, and 2.12 times greater than 
that of Group C. The relative bioavailability of ligustrazine 
ethosome patches in this study was 209.45%, but that of 
the conventional ligustrazine patches was only 98.63%. 
This demonstrated that ligustrazine ethosome patches could 
improve drug absorption and bioavailability compared 
with the other two preparations. In addition, the T1/2β value 
was 1.94 hours in Group A, 18.99 hours in Group B, and 
29.89 hours in Group C, respectively. Compared with orally 
administered ligustrazine, ligustrazine ethosome patches 
had a significantly longer elimination half-life and more 
stable plasma concentrations at the high level. Although the 
elimination half-life of conventional ligustrazine patches was 
longer than that of ligustrazine ethosome patches, the plasma 
concentration was lower. Therefore, ligustrazine ethosome 
patches have an obvious advantage compared with the other 
two preparations.
Discussion
The combined methods of ethanol injection and sonication 
were used in the preparation of ligustrazine ethosomes in 
this study. We found that the particle size of the ligustrazine 
ethosomes decreased as ethanol concentration increased, 
but increased as the phospholipid concentration increased. 
Ligustrazine is a water-soluble drug. Ethanol could increase 
the solubility of ligustrazine, and the entrapment efficiency 
of the ethosomes containing a water-soluble drug was higher 
than that of conventional vesicle preparations.7 Compared 
with liposomes, the most striking feature of ethosomes is the 
relatively high concentration of ethanol. On the one hand, the 
presence of ethanol increases the flexibility of the lipid bilayer 
in ethosomes; on the other hand, the interaction between 
e  thanol and the lipid of the stratum corneum reduces the phase 
transition temperature of the latter, thus promoting mobility 
and drug penetration. It has been reported that a low ethanol 
concentration is not conducive to entrapment of drugs in 
ethosomes, thus affecting drug loading, and that a high alcohol 
concentration is not conducive to ethosome formation because 
p  hospholipids can easily dissolve in ethanol. Therefore, 
the ethanol c  oncentration in the ethosome system should not 
be too high, and generally should be kept below 45%.16
The molecular weight of the polymer is an important 
determinant of the properties of an acrylic pressure-
sensitive adhesive. The crosslinking formed by the action 
between succinic acid and the quaternary ammonium group 
Table 1 The in vitro release result of ligustrazine ethosome patches
M Amount of cumulative release (μg/cm2)
2 hours 4 hours 6 hours 12 hours 24 hours
M1 131.6 161.4 168.6 183.6 189.0
M2 150.0 184.4 188.3 205.9 210.5
M3 127.6 155.9 176.4 195.0 206.0
M4 146.2 178.1 186.0 202.3 206.1
M5 124.9 146.0 157.0 176.5 181.9
M6 129.4 150.0 163.2 188.6 191.8
X ± s 134.9 ± 10.6 163.4 ± 14.8 173.2 ± 12.5 192.0 ± 11.2 197.5 ± 11.5
Table 2 cumulative transdermal and steady-state permeation rates
Q value (μg/cm2) at different times (hours)
1 2 3 4 6 8 10 12 16 24
7.2 ± 0.9 19.6 ± 1.9 31.9 ± 4.2 44.4 ± 7.1 65 ± 9 83 ± 10 98 ± 13 113 ± 12 141 ± 12 183 ± 18International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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of acrylic resin IV may enhance the molecular weight. 
  Generally, persistent adhesivity increases as the amount of 
crosslinking agent increases. Further increasing the amount 
of the   crosslinking agent will increase both the vitrification 
temperature and the rigidity of the glue film, leading to a 
decrease in adhesivity of the patches. In this study, succinic 
acid and triethyl citrate were added to the polyacrylic acid 
resin to adjust the initial adhesivity, persistent adhesivity, and 
cohesive strength of the acrylic pressure-sensitive adhesive, 
so as to improve the biocompatibility of the acrylic pressure-
sensitive adhesive patches.
Regardless of whether transdermal absorption has a 
systemic action or a local effect, drugs should pass through 
the stratum corneum. However, due to the barrier effect of 
the stratum corneum, many drugs cannot play a full role. 
Ethosomes have been used for transdermal drug delivery in 
recent years because they can enable a drug to pass through 
the skin and increase the accumulation of drug in the skin.16 
According to one report,15 the steady-state transdermal rate 
of trihexyphenidyl hydrochloride ethosomes composed 
of phospholipid, ethanol, and water increased by 87-fold 
c  ompared with normal liposomes.
In vitro transdermal release rates are important i  ndicators 
of quality for a transdermal drug-delivery system. The 
transdermal drug absorption process can be divided into 
three stages, ie, release from the matrix, passage through 
the stratum corneum barrier, epidermis, and dermis, and 
a  bsorption by blood vessels. Some active ingredients of 
C  hinese traditional medicines cannot achieve a therapeutic 
dose by passive absorption alone. Therefore, a suitable 
method to promote penetration is needed. Ligustrazine was 
prepared in ethosome patches in this study. The cumulative 
amount of the   transdermal drug was regarded as an e  valuation 
index in our in vitro transdermal experiment. A self-  prepared 
Franz d  iffusion cell was used. According to the test results, 
the 24-hour cumulative amount of transdermal drug release 
was up to 183 ± 18 µg/cm2, which greatly increased the 
t  ransdermal effect of ligustrazine. In our release test, 
the in vitro release curve of ligustrazine ethosome patches 
was consistent with the Higuchi equation within 24 hours, 
which indicated a good sustained-release effect.
In order to improve the safety and bioavailability of 
ligustrazine and to avoid the first-pass hepatic effect of oral 
administration, the transdermal drug-delivery system has 
been used in medical treatment.17 In that study, the AUC of 
the ligustrazine ethosome patch group was 2.09-fold greater 
than that of the oral ligustrazine group, and was 2.12-fold 
greater than that of the conventional ligustrazine patch group. 
Compared with oral ligustrazine, the relative bioavailability 
of ligustrazine ethosomes was up to 209.45%, while that of 
a conventional transdermal patch was only 98.63%. There 
was little difference in AUC values between the conventional 
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Figure 2 Plasma concentration–time curve of three ligustrazine preparations (A: Intragastric administration group of ligustrazine; B: Transdermal drug delivery goup of 
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ligustrazine patch group and the oral ligustrazine group, 
indicating a poor transdermal effect of the conventional 
ligustrazine patch. These results indicate that ligustrazine 
ethosome patches play a role in promoting drug absorption 
and increasing bioavailability compared with the other two 
preparations.
In a toxicity test of ethosomes, Paolino et al studied the 
difference between blank ethosomes, sodium chloride (0.9%, 
v/v), and ethanol–water solution. They found that an ethanol–
water solution caused significant skin e  rythema, whereas 
blank ethosomes did not, even in a high c  oncentration of 
ethanol. This indicates that ethosomes cause no significant 
irritation to human skin.18 Histological testing of erythro-
mycin ethosomes also revealed that these ethosomes caused 
no damage to skin.12 For testosterone ethosomes (including 
25% ethanol, w/w), skin irritation was not found during the 
treatment period.19 Moreover, in a toxicity test of fibroblasts, 
ethosomes caused no significant toxicity to cultured cells 
in vitro.20 For these reasons, we can conclude that transder-
mal drug delivery via ethosomes has potentially extensive 
applications in medicine as a result of its high e  fficiency, 
convenient administration, and limited toxicity.
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